Bottom line
DLHAX vs RYHIX: the short answer
DLHAX (Nomura Healthcare Fund) and RYHIX (Health Care Fund) are both mutual funds.
DLHAX is cheaper at 1.21% vs 1.38% — a difference of $17 a year per $10,000 invested.
Over five years, DLHAX returned +6.2% a year vs +5.1% for RYHIX.
DLHAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
DLHAX vs RYHIX side by side
| DLHAX | RYHIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Voya | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.21% | 1.38% |
| Annual cost per $10k | $121 | $138 |
| 10-yr cost on $10k (prospectus) | $2,006 | $1,709 |
| Max front load | 5.75% | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +15.1% | +14.4% |
| 5-yr return (annualized) | +6.2% | +5.1% |
| 10-yr return (annualized) | +9.5% | +7.9% |
| Best quarter | +21.5% | +18.7% |
| Worst quarter | −14.9% | −14.4% |
| Net assets (fund) | $750.2M | $19.4M |
| Number of holdings | 108 | 135 |
| Portfolio turnover | 4% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | DLHAX | RYHIX | Difference |
|---|---|---|---|
| 2025 | +22.1% | +14.4% | +7.7% |
| 2024 | +8.5% | +0.6% | +7.9% |
| 2023 | +4.2% | +5.8% | −1.6% |
| 2022 | −1.3% | −11.6% | +10.3% |
| 2021 | −5.3% | +19.2% | −24.6% |
| 2020 | +11.1% | +18.9% | −7.8% |
| 2019 | +31.5% | +22.8% | +8.8% |
| 2018 | −0.8% | +1.6% | −2.4% |
| 2017 | +32.0% | +23.5% | +8.5% |
| 2016 | −4.3% | −9.4% | +5.0% |
Source: Fund prospectus bar charts
Holdings overlap
11 of DLHAX's top 25 holdings also appear in RYHIX's top 25.
| Holding | DLHAX | RYHIX |
|---|---|---|
| Abbvie Inc | 4.19% | 2.52% |
| Eli Lilly & Company | 4.16% | 3.63% |
| Regeneron Pharmaceuticals Inc | 3.91% | 0.90% |
| Unitedhealth Group Inc | 3.88% | 2.22% |
| Pfizer Inc | 3.84% | 1.25% |
| Merck & Company Inc | 3.68% | 2.04% |
| Gilead Sciences Inc | 3.54% | 1.39% |
| Elevance Health Inc | 3.25% | 1.02% |
| Amgen Inc | 2.27% | 1.56% |
| Vertex Pharmaceuticals Inc | 1.66% | 1.34% |
| Boston Scientific Corp | 1.42% | 0.86% |
Source: SEC Form N-PORT
DLHAX top 10
- Ucb Sa — 5.19%
- Abbvie Inc — 4.19%
- Eli Lilly & Company — 4.16%
- Regeneron Pharmaceuticals Inc — 3.91%
- Unitedhealth Group Inc — 3.88%
- Pfizer Inc — 3.84%
- Merck & Company Inc — 3.68%
- Gilead Sciences Inc — 3.54%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between DLHAX and RYHIX?
Which is cheaper, DLHAX or RYHIX?
Should I own both DLHAX and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.